UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): January 26, 2021
Kiwa
Bio-Tech Products Group Corporation
(Exact
Name of Registrant as Specified in Charter)
| Nevada |
|
000-33167 |
|
77-0632186 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 3200
Guasti Road, Ste. 100, Ontario, CA |
|
91761 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (626) 715-5855
(Former
name or former address, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of exchange on which registered |
| Common
Stock par value $0.001 |
|
KWBT |
|
PINK |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| [ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| [ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| [ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| [ ] |
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c) |
ITEM
4.01 CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT
On
January 25, 2021, the Board of Directors of Kiwa Bio-tech Products Group Corporation (the “Registrant”) received the
formal notice that our independent auditors, Friedman LLP (“Friedman”), had made the decision to resign as our independent
accountants effective January 20, 2021. On January 20, 2021, the Board of Directors voted unanimously to accept the resignation.
Friedman
audited the financial statements of the Company for the last three fiscal years ended December 31, 2017, 2018 and 2019. The reports
of Friedman on such financial statements did not contain an adverse opinion or disclaimer of opinion and was not qualified or
modified as to uncertainty, audit scope or accounting principles.
For
the past three fiscal years and subsequent interim periods though the date of resignation, there have been no disagreements with
Friedman on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure,
which disagreement, if not resolved to the satisfaction of Friedman., would have caused them to make reference thereto in their
report on the financial statements.
Registrant
has requested that Friedman LLP furnish it with a letter addressed to the Securities and Exchange Commission stating whether or
not it agrees with the statements in this Item 4.01. A copy of Friedman LLP’s letter to the Securities and Exchange Commission
is included as an exhibit to this filing.
Item
9.01. Financial Statements and Exhibits.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
January 26, 2021
| |
Kiwa
Bio-Tech Products Group Corporation |
| |
|
|
| |
|
/s/
Wade Li |
| |
By: |
Wade
Li |
| |
Title: |
Chief
Executive Officer |
